机译:P3.02B-108评估基于CFDNA的测定检测EGFR-TKI难治性NSCLC患者EGFR T790M突变的临床可用性评估
Department of Respiratory Medicine and Rheumatology Institute of Biomedical Sciences Tokushima;
Biomarker Research Taiho Pharmaceutical Co. ltd.;
Biomarker Research Taiho Pharmaceutical Co. ltd.;
Department of Respiratory Medicine and Rheumatology Institute of Biomedical Sciences Tokushima;
Department of Respiratory Medicine and Rheumatology Institute of Biomedical Sciences Tokushima;
Department of Respiratory Medicine and Rheumatology Institute of Biomedical Sciences Tokushima;
Department of Respiratory Medicine and Rheumatology Institute of Biomedical Sciences Tokushima;
机译:P3.02B-108评估基于CFDNA的测定检测EGFR-TKI难治性NSCLC患者EGFR T790M突变的临床可用性评估
机译:选择性基因扩增可检测已发展为表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药的晚期非小细胞肺癌(NSCLC)患者血浆中的T790M突变
机译:用于检测NSCLC患者中EGFR T790M突变的数字PCR检测方法的发展
机译:单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
机译:选择性基因扩增可检测患有表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药的晚期非小细胞肺癌(NSCLC)患者血浆中的T790M突变
机译:选择性基因扩增以检测具有开发表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)抗性的晚期非小细胞肺癌(NSCLC)血浆中的血浆T790M突变